Editas

In exchange, Editas has the exclusive right to be the first to negotiate for licenses to genome-editing inventions that arise from the sponsored research.

The company — which was cofounded by David Liu, Feng Zhang, and Keith Joung — has licensed base editing technology from Harvard and the Broad Institute.

Ready to Go, But?

Technology Review writes that though CRISPR trials in people are beginning, studies in monkeys haven't provided much data.

On the Verge

The Financial Times reports that CRISPR-based biotechs are about to start human studies of gene-editing treatments.

The wide-ranging discussion with witnesses from Stanford, Johns Hopkins, and Editas Medicine touched on recent advances in research and questions of safety.

In letters, CRISPR companies respond to a Nature Methods report of off-target editing effects, Technology Review reports.

The company intends to use part of the proceeds of the offering to advance programs including one in Leber congenital amaurosis 10.

The firm plans to sell 4 million shares of common stock to support preclinical studies and clinical trials of CRISPR-based human therapies, among other uses.

Allergan will have the exclusive rights to license certain of Editas' CRISPR genome editing-based treatments for eye diseases.

The University of California-led party can still appeal the decision from the US Patent and Trademark Office, but it has been dealt a major setback.

Pages

Sometimes genetic tests give inconclusive results and provide little reassurance to patients, the Associated Press reports.

Vox wonders whether gene-editing crops will be viewed similarly as genetically modified organisms of if people will give them a try.

In Science this week: research regulation and reporting requirement reform, and more.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.